Tomoki Yoneyama

789 total citations
24 papers, 545 citations indexed

About

Tomoki Yoneyama is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Tomoki Yoneyama has authored 24 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in Tomoki Yoneyama's work include Drug Transport and Resistance Mechanisms (4 papers), Helicobacter pylori-related gastroenterology studies (3 papers) and Cancer Diagnosis and Treatment (3 papers). Tomoki Yoneyama is often cited by papers focused on Drug Transport and Resistance Mechanisms (4 papers), Helicobacter pylori-related gastroenterology studies (3 papers) and Cancer Diagnosis and Treatment (3 papers). Tomoki Yoneyama collaborates with scholars based in Japan, United States and United Kingdom. Tomoki Yoneyama's co-authors include Hiroyuki Okamoto, Mark G. Hibberd, Richard O. Jenkins, Helen Jenkins, Kiyoshi Ashida, Akira Nishimura, Yoichiro Ogama, Steve Warrington, Yuichi Sakurai and Shin Irie and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Controlled Release.

In The Last Decade

Tomoki Yoneyama

24 papers receiving 534 citations

Peers

Countries citing papers authored by Tomoki Yoneyama

Since Specialization

Citations

This map shows the geographic impact of Tomoki Yoneyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoki Yoneyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoki Yoneyama more than expected).

Fields of papers citing papers by Tomoki Yoneyama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoki Yoneyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoki Yoneyama. The network helps show where Tomoki Yoneyama may publish in the future.

Co-authorship network of co-authors of Tomoki Yoneyama

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoki Yoneyama. A scholar is included among the top collaborators of Tomoki Yoneyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoki Yoneyama. Tomoki Yoneyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Establishment of a Biomarker‐Directed Clinical Endpoint Model for Early‐Stage Parkinson's Disease Patients 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), Serge Guzy, Tomoki Yoneyama, (unknown), (unknown), Sergio Iadevaia, Dipak Barua, Yaming Hang, (unknown), Christina Boucher, Majid Vakilynejad, Stephan Schmidt, Valvanera Vozmediano	2
2	Advanced translational PBPK model for transferrin receptor-mediated drug delivery to the brain 2023 ·Journal of Controlled Release ·Sho Sato, Siyu Liu, Akihiko Goto, Tomoki Yoneyama, (unknown), S. Yamamoto, Hideki Hirabayashi, Shinji Iwasaki, Hiroyuki Kusuhara	14
3	Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma 2022 ·PLoS Computational Biology ·Tomoki Yoneyama, Mi‐Sook Kim, Konstantin Piatkov, Haiqing Wang, Andy Z. X. Zhu	9
4	1153 Preclinical activity of C-C chemokine receptor 2 (CCR2)-targeted immune stimulating antibody conjugate (ISAC), motivating clinical testing of TAK-500 2022 ·Regular and Young Investigator Award Abstracts ·Vicky A. Appleman, Atsushi Matsuda, Michelle L. Ganno, (unknown), (unknown), (unknown), (unknown), (unknown), Min Young Lee, Linlin Dong, Jian Huang, (unknown), Dong Mei Zhang, Jianing Wang, He N. Xu, Tomoki Yoneyama, Konstantin Piatkov, Carole E. Harbison, Adnan O. Abu‐Yousif	4
5	Sinusoidal Uptake Determines the Hepatic Clearance of Pevonedistat (TAK-924) as Explained by Extended Clearance Model 2022 ·Drug Metabolism and Disposition ·(unknown), (unknown), Lawrence H. Cohen, Tomoki Yoneyama, (unknown), Robert W. Yucha, Swapan K. Chowdhury, Paresh P. Chothe	3
6	Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors 2022 ·Cancer Research ·Jennifer R. Diamond, Jason T. Henry, Gerald S. Falchook, Anthony J. Olszanski, Harshabad Singh, E. Jane Leonard, Richard C. Gregory, Vicky A. Appleman, John P. Gibbs, Carole E. Harbison, Cong Li, (unknown), Tomoki Yoneyama, (unknown), Vincent Chung	7
7	Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice 2020 ·Pharmaceutical Research ·Tomoki Yoneyama, Sho Sato, (unknown), Rosa Fradley, (unknown), (unknown), (unknown), Toshal R. Patel, Yoshihiko Tagawa, Toshiya Moriwaki, Satoru Asahi	7
8	A Citrulline‐Based Translational Population System Toxicology Model for Gastrointestinal‐Related Adverse Events Associated With Anticancer Treatments 2019 ·CPT Pharmacometrics & Systems Pharmacology ·Tomoki Yoneyama, (unknown), (unknown), (unknown), (unknown), Andy Z. X. Zhu	3
9	A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry 2016 ·Journal of Chromatography B ·Tomoki Yoneyama, (unknown), (unknown), Takahiro Kondo, Satoru Asahi	29
10	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects 2015 ·Clinical and Translational Gastroenterology ·Yuuichi Sakurai, Akira Nishimura, (unknown), Mark G. Hibberd, Richard O. Jenkins, Hiroyuki Okamoto, Tomoki Yoneyama, Helen Jenkins, Kiyoshi Ashida, Shin Irie, Jörg Täubel	141
11	Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects 2015 ·Alimentary Pharmacology & Therapeutics ·Helen Jenkins, Yuichi Sakurai, Akira Nishimura, Hiroyuki Okamoto, Mark G. Hibberd, Richard O. Jenkins, Tomoki Yoneyama, Kiyoshi Ashida, Yoichiro Ogama, Steve Warrington	236
12	Tiered Approaches to Chromatographic Bioanalytical Method Performance Evaluation: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team 2014 ·The AAPS Journal ·Steve Lowes, (unknown), Mohammed Jemal, Joseph C. Marini, (unknown), Ronald E. Shoup, Puran Singhal, Philip Timmerman, Tomoki Yoneyama, Naidong Weng, Dieter Zimmer	15
13	Retrospective Data Analysis and Proposal of a Practical Acceptance Criterion for Inter-laboratory Cross-validation of Bioanalytical Methods Using Liquid Chromatography/Tandem Mass Spectrometry 2014 ·The AAPS Journal ·Tomoki Yoneyama, Takashi Kudo, (unknown), (unknown), Takahiro Kondo	4
14	In vivo relationship between thalamic nicotinic acetylcholine receptor occupancy rates and antiallodynic effects in a rat model of neuropathic pain: Persistent agonist binding inhibits the expression of antiallodynic effects 2010 ·Synapse ·Masashi Ueda, Yasuhiko Iida, Tomoki Yoneyama, Tomoki Kawai, Mikako Ogawa, Yasuhiro Magata, Hideo Saji	5
15	Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti‐allodynic effects 2010 ·British Journal of Pharmacology ·Masashi Ueda, Yuki Iida, (unknown), Tomoki Yoneyama, Mikako Ogawa, Yasuhiro Magata, Hiroshi Nishimura, (unknown), Hideo Saji	22
16	Studies on 1-alkylamine adduct formation in electrospray ionization mass spectrometry for quantitative analysis 2008 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), Tomoki Yoneyama, Takahiro Kondo	3
17	Extracorporeal Xenoperfusion of the Pig Liver As a Liver Assist Device: Effects of Prostaglandin E1 and Soluble Complement Receptor Type 1 1998 ·Transplantation Proceedings ·Tsukasa Yagi, S Satoh, Akiyoshi Kanazawa, (unknown), (unknown), Tomoki Yoneyama, Ryuta Nishitai, Hiroaki Terajima, Iwao Ikai, Yasuyuki Shimahara, Yoshio Yamaoka	3
18	[Clinical and basic studies on the treatment of cancer metastasis]. 1987 ·PubMed ·(unknown), Tomoki Yoneyama, Takashi Naruke, Ryosuke Tsuchiya, Tomoyuki Goya, Naoki Miyazawa	2
19	[Bronchoplasty in surgical management of lung neoplasms]. 1976 ·PubMed ·Takashi Naruke, Tomoki Yoneyama, Tetsuya Ogata, K Suemasu	1
20	[Disappearance of the symptoms of clubbing of fingers and toes following the surgery of lung cancer]. 1970 ·PubMed ·(unknown), (unknown), Tomoki Yoneyama, (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact